Marc A Meier1, Manuel Ottiger1, Alaadin Vögeli1, Christian Steuer2, Luca Bernasconi2, Robert Thomann3, Mirjam Christ-Crain4, Christoph Henzen5, Claus Hoess6, Werner Zimmerli7, Andreas Huber2, Beat Mueller1, Philipp Schuetz8. 1. Medical University Department, Kantonsspital Aarau, Medical faculty, University of Basel, Tellstrasse, 5001, Aarau and Basel, Switzerland. 2. Department of Laboratory Medicine, Kantonsspital Aarau, Aarau, Switzerland. 3. Medical Department, Buergerspital Solothurn, Solothurn, Switzerland. 4. Medical University Department, University Hospital Basel, Basel, Switzerland. 5. Medical Department, Kantonsspital Luzern, Lucerne, Switzerland. 6. Medical Department, Kantonsspital Muensterlingen, Muensterlingen, Switzerland. 7. Medical University Department, Kantonsspital Baselland, Liestal, Switzerland. 8. Medical University Department, Kantonsspital Aarau, Medical faculty, University of Basel, Tellstrasse, 5001, Aarau and Basel, Switzerland. schuetzph@gmail.com.
Abstract
BACKGROUND/ INTRODUCTION: Indoleamine 2,3-dioxygenase (IDO) metabolizes tryptophan to kynurenine. An increase of its activity is associated with severity in patients with pneumonia. In chronic obstructive pulmonary disease (COPD) patients, an elevation of serotonin has been reported. Experimental models showed that cigarette smoke inhibits monoamine oxidase (MAO) leading to higher levels of serotonin. We investigated the prognostic ability of tryptophan, serotonin, kynurenine, IDO, and tryptophan hydroxylase (TPH) to predict short- and long-term outcomes in patients with a COPD exacerbation. METHODS: We measured tryptophan, serotonin, and kynurenine on admission plasma samples in patients with a COPD exacerbation from a previous trial by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). IDO and TPH were calculated as ratios of kynurenine over tryptophan, and serotonin over tryptophan, respectively. We studied their association with parameters measured in clinical routine at emergency department admission representing inflammation (C-reactive protein [CRP]), infection (procalcitonin [PCT]), oxygenation (SpO2), as well as patients' clinical outcome, confirmed by structured phone interviews. RESULTS: Mortality in the 149 included patients was 53.7% within six years of follow-up. While IDO activity showed strong positive correlations, tryptophan was negatively correlated with CRP and PCT. For 30-day adverse outcome defined as death and/or intensive care unit (ICU) admission, a multivariate regression analysis adjusted for age and comorbidities found strong associations for IDO activity (adjusted odds ratios of 31.4 (95%CI 1.1-857), p = 0.041) and TPH (adjusted odds ratios 27.0 (95%CI 2.2-327), p = 0.010). TPH also showed a significant association with mortality at 18 months, (hazard ratio 2.61 (95%CI 1.2-5.8), p = 0.020). CONCLUSION: In hospitalized patients with a COPD exacerbation, higher IDO and TPH activities independently predicted adverse short-term outcomes and TPH levels were also predictive of 18-month mortality. Whether therapeutic modulation of the serotonin pathway has positive effects on outcome needs further investigation.
BACKGROUND/ INTRODUCTION:Indoleamine 2,3-dioxygenase (IDO) metabolizes tryptophan to kynurenine. An increase of its activity is associated with severity in patients with pneumonia. In chronic obstructive pulmonary disease (COPD) patients, an elevation of serotonin has been reported. Experimental models showed that cigarette smoke inhibits monoamine oxidase (MAO) leading to higher levels of serotonin. We investigated the prognostic ability of tryptophan, serotonin, kynurenine, IDO, and tryptophan hydroxylase (TPH) to predict short- and long-term outcomes in patients with a COPD exacerbation. METHODS: We measured tryptophan, serotonin, and kynurenine on admission plasma samples in patients with a COPD exacerbation from a previous trial by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). IDO and TPH were calculated as ratios of kynurenine over tryptophan, and serotonin over tryptophan, respectively. We studied their association with parameters measured in clinical routine at emergency department admission representing inflammation (C-reactive protein [CRP]), infection (procalcitonin [PCT]), oxygenation (SpO2), as well as patients' clinical outcome, confirmed by structured phone interviews. RESULTS: Mortality in the 149 included patients was 53.7% within six years of follow-up. While IDO activity showed strong positive correlations, tryptophan was negatively correlated with CRP and PCT. For 30-day adverse outcome defined as death and/or intensive care unit (ICU) admission, a multivariate regression analysis adjusted for age and comorbidities found strong associations for IDO activity (adjusted odds ratios of 31.4 (95%CI 1.1-857), p = 0.041) and TPH (adjusted odds ratios 27.0 (95%CI 2.2-327), p = 0.010). TPH also showed a significant association with mortality at 18 months, (hazard ratio 2.61 (95%CI 1.2-5.8), p = 0.020). CONCLUSION: In hospitalized patients with a COPD exacerbation, higher IDO and TPH activities independently predicted adverse short-term outcomes and TPH levels were also predictive of 18-month mortality. Whether therapeutic modulation of the serotonin pathway has positive effects on outcome needs further investigation.
Authors: Jörg C Schefold; Jan-Philip Zeden; Christina Fotopoulou; Stephan von Haehling; Rene Pschowski; Dietrich Hasper; Hans-Dieter Volk; Christine Schuett; Petra Reinke Journal: Nephrol Dial Transplant Date: 2009-01-20 Impact factor: 5.992
Authors: Philipp Schuetz; Mirjam Christ-Crain; Marcel Wolbers; Ursula Schild; Robert Thomann; Claudine Falconnier; Isabelle Widmer; Stefanie Neidert; Claudine A Blum; Ronald Schönenberger; Christoph Henzen; Thomas Bregenzer; Claus Hoess; Martin Krause; Heiner C Bucher; Werner Zimmerli; Beat Müller Journal: BMC Health Serv Res Date: 2007-07-05 Impact factor: 2.655
Authors: Huiwei Zhu; Abu S Abdullah; Jingyi He; Jianxiong Xi; Yimeng Mao; Yitian Feng; Qianyi Xiao; Pinpin Zheng Journal: Int J Environ Res Public Health Date: 2021-01-15 Impact factor: 3.390
Authors: Chris H Wendt; Sandra Castro-Pearson; Jennifer Proper; Sarah Pett; Timothy J Griffin; Virginia Kan; Javier Carbone; Nikolaos Koulouris; Cavan Reilly; James D Neaton Journal: PLoS One Date: 2021-04-02 Impact factor: 3.240
Authors: Marisa R Pinson; Nicolaas E P Deutz; Rajesh Harrykissoon; Anthony J Zachria; Mariëlle P K J Engelen Journal: BMC Pulm Med Date: 2021-11-07 Impact factor: 3.317